However, one of the drawbacks of IV TCZ is the requirement for monthly infusions, which is inherently inconvenient for the patient and associated with increased cost. Subcutaneous (SC) TCZ has now been approved following two clinical trials which showed similar efficacy and safety compared to IV TCZ, and better efficacy compared to placebo (SUMMACTA and
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic autoimmune condition characterized by joint inflammation, although extra-articular features are common. RA affects approximately 1% of the adult population worldwide and is more common in women [1, 2] . The incidence of RA in the UK is 36 per 100,000 women and 14 per 100,000 men per year [1, 2] and RA may lead to significant disability, reduced quality of life, and increased mortality [1, [3] [4] [5] . Furthermore, it has a significant impact on work productivity, with approximately one-third of patients having to leave employment within 2 years of diagnosis [6] .
Joint Involvement in Rheumatoid Arthritis
Although typically a disease of the hands and feet, RA may affect any synovial joint.
Inflammation of the synovium, followed by progressive degradation of cartilage and subsequent bone erosion are the hallmark of active untreated disease.
Systemic Effects of Rheumatoid Arthritis
In addition to joint destruction, RA can result in a variety of extra-articular manifestations including anemia, localized and generalized osteoporosis [7, 8] , nodulosis, eye disease, and pulmonary and cardiovascular (CV) disease [9, 10] . Being diagnosed with RA is an independent risk factor for atherosclerosis (similar in severity to type 2 diabetes mellitus) due to chronic, systemic inflammation [11] [12] [13] . CV disease has emerged as the number one cause of mortality in patients with RA [14, 15] .
Immunopathogenesis
The articular and extra-articular manifestations of RA are caused at a molecular level by increased levels of pro-inflammatory cells, cytokines, and autoantibody production [8] .
Pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 17 (IL-17), interferon gamma (IFN-c), and transforming growth factor beta (TGF-b), can stimulate the release of further cytokines [16] [17] [18] [19] , leading to excessive cellular activation and migration into the synovium and sustained inflammation [16, 17, 19] .
THE ROLE OF IL-6 IN RHEUMATOID ARTHRITIS
IL-6 is one of the chief pro-inflammatory cytokines found in the joints and sera of patients with RA [20] [21] [22] [23] . A number of cell types produce and release IL-6, including activated macrophages, synovial fibroblasts, and T and B cells [8, [24] [25] [26] . Increased levels of IL-6 correlate with inflammation, disease activity, and radiological damage [8, 24, [27] [28] [29] [30] . Furthermore, the decrease in serum IL-6 levels in the first 12 months of therapy with disease-modifying agents (DMARDs) is a powerful prognostic marker for clinical outcomes [28] .
CURRENT TREATMENTS FOR RHEUMATOID ARTHRITIS
Non-steroidal Anti-inflammatory Drugs and Traditional DMARDs
Treatment for RA should focus on minimizing the signs and symptoms of the disease (pain, stiffness, and swelling of the joints) and on preventing or minimizing joint damage to preserve functionality and quality of life. In addition, reducing the extra-articular manifestations and implicitly reducing the premature mortality associated with the condition is critical [31, 32] .
Suppression of inflammation is the central element of RA management, with remission (defined as the complete suppression of inflammation and prevention of joint destruction) being the ultimate goal of therapy [16, 19, 33] . Non-steroidal antiinflammatory drugs (NSAIDs) may provide fast and effective relief of symptoms, but do not alter the disease course. The cornerstone of therapy, therefore, is DMARDs, which should be instituted as early as possible to prevent long-term joint damage [34] [35] [36] . For safety and efficacy reasons, patients should be frequently monitored and treatment altered accordingly, adopting a treat to target strategy [37] .
Although highly effective in many cases, 
SAFETY OF SUBCUTANEOUS TOCILIZUMAB
The safety of SC TCZ was also assessed in the SUMMACTA (Table 1 ) and BREVACTA studies. 
Dose interruption or study withdrawal because of ISR, n 0 0
Reproduced from Burmester et al.
[50] with permission from BMJ Publishing Group Ltd. AE adverse event, ISR r injection site reaction, IV intravenous, PY patient-years, qw r every week, q4w r every 4 weeks, SAE serious adverse event, SC subcutaneous, SI serious infection a Serious hypersensitivity was defined as an SAE occurring during or within 24 h of the injection or infusion, excluding ISR, and evaluated as 'related' to study treatment by the investigator b Of the three events in the tocilizumab IV group, one was cellulitis and one was retinal artery occlusion; these two events were not considered consistent with a serious hypersensitivity reaction respiratory tract infection (7.3% TCZ SC and 11.6% TCZ IV). Serious infections were rare, but reported in both groups (pneumonia-two cases in each group). Septic arthritis occurred in two patients in the IV group, with one case progressing to sepsis and death. No deaths were reported in the SC group (0/631; 1/631 in the IV group). The most common cause for study discontinuation due to side effects was infection in both groups (1.1% TCZ SC and 1.3% TCZ IV).
The use of TCZ leads to a strong decrease in Fig. 2 ).
PRACTICAL ASPECTS OF SUBCUTANEOUS FORMULATION
The advantages of SC formulations include convenience and reduced cost compared with IV therapies. Time off work or usual activities to attend pre-booked IV infusions requires significant infrastructure and is not patient focused.
Self was reported.
CONCLUSION
Following the success of IV TCZ, the arrival of SC TCZ is a welcome addition to the arsenal to combat the morbidity and premature mortality associated with RA. The efficacy of SC TCZ in both monotherapy and combination therapy and the acceptable safety profile are reassuring; however, longer-term data are required. Certain groups of patients may benefit, especially those intolerant to traditional DMARDs. Increasingly, SC TCZ will be incorporated into management paradigms to optimize the outcomes for all RA patients.
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